Related Experiment Video

Updated: May 6, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.6K

Small-molecule inhibitors of PKR improve glucose homeostasis in obese diabetic mice

Takahisa Nakamura1, Alessandro Arduini, Brenna Baccaro

  • 1Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA.

Diabetes
|October 24, 2013
PubMed

Insights

Targeting double-stranded RNA-dependent kinase (PKR) with small-molecule inhibitors effectively treats insulin resistance and type 2 diabetes. This approach reduces inflammation and improves glucose metabolism in obese models, offering a promising therapeutic strategy.

Area of Science:

  • Metabolic disease research
  • Pharmacology
  • Molecular biology

Background:

  • Obesity and metabolic diseases, including insulin resistance and type 2 diabetes, are significant global health issues with limited treatments.
  • Double-stranded RNA-dependent kinase (PKR) is implicated in nutrient sensing and metabolic inflammation, with pathological activation observed in obese humans.
  • PKR is a potential therapeutic target for metabolic disorders.

Purpose of the Study:

  • To investigate the efficacy of two small-molecule PKR inhibitors in treating insulin resistance and type 2 diabetes.
  • To evaluate PKR inhibition's effects on cellular and in vivo models of obesity and insulin resistance.

Main Methods:

  • Utilized cell cultures and a mouse model of severe obesity and insulin resistance.
  • Administered two distinct small-molecule PKR inhibitors.
  • Assessed Jun NH2-terminal kinase activation, insulin receptor substrate 1 phosphorylation, adipose tissue inflammation, insulin sensitivity, and glucose intolerance.

Main Results:

  • PKR inhibition reduced stress-induced Jun NH2-terminal kinase activation and insulin receptor substrate 1 serine phosphorylation.
  • Treatment with PKR inhibitors decreased adipose tissue inflammation in obese mice.
  • PKR inhibition improved insulin sensitivity and glucose tolerance in established obesity and insulin resistance models.

Conclusions:

  • Pharmacological targeting of PKR demonstrates potential as an effective therapeutic strategy for insulin resistance and type 2 diabetes.
  • PKR inhibitors offer a promising avenue for managing metabolic dysfunction associated with obesity.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.7K
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

2.6K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
958
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K